Search

Displaying results 1491 - 1500 of 10000 in total
  1. Drug

    Influenza B virus B/Washington/02/2019 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB15620
    ApprovedInvestigational

    Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. … A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses.

    Mixtures: Influvac Tetra, suspension for injection in pre-filled syringe, Vaxigrip Tetra, Suspension for Injection in Pre-filled Syringe
  2. Drug

    Vorasidenib

    go.drugbank.com/drugs/DB17097
    ApprovedInvestigational

    [A264209] Vorasidenib was first approved by the FDA on August 6, 2024, for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.[L51144] … Vorasidenib is a first-in-class dual isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor.

  3. Drug

    Pitavastatin

    go.drugbank.com/drugs/DB08860
    ApprovedInvestigational

    as well as the need for surgical revascularization or angioplasty following a heart attack. … events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks.

    Categories: Hypolipidemic Agents Indicated for Hyperlipidemia
  4. Drug

    Buclizine

    go.drugbank.com/drugs/DB00354
    Approved

    Buclizine is an antihistamine medication with both antiemetic and anticholinergic effects , belonging to the piperazine derivative family of drugs. It was manufactured by Stuart Pharms and initially approved by the FDA in 1957. Following...

    Categories: Antihistamines for Systemic Use
  5. Drug

    Tisagenlecleucel

    go.drugbank.com/drugs/DB13881
    ApprovedInvestigational

    Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy, or a CAR-T cell therapy for B-cell acute lymphoblastic leukemia. … In a multicenter clinical trial involving pediatric and young adult patients with relapsed or refractory B-cell precursor ALL, the overall remission rate within three months of treatment was 83 percent

  6. Drug

    Niclosamide

    go.drugbank.com/drugs/DB06803
    ApprovedInvestigationalVet approved

    Niclosamide is an antihelminthic used for the treatment of tapeworm infections. … Helminths (worms) are multicellular organisms that infect very large numbers of humans and cause a broad range of diseases.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Poliovirus type 1 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10795
    ApprovedInvestigational

    Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis … The vaccine contains purified and inactivated poliovirus type 1 that were grown from a continuous line of monkey kidney cells.

    Mixtures: Hexaxim Suspension for Injection, BOOSTRIX POLIO SUSPENSION FOR INJECTION
  8. Drug

    Poliovirus type 3 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10797
    ApprovedInvestigational

    Poliovirus type 3 antigen is a suspension of poliovirus Type 3 (Saukett) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis … The vaccine contains purified and inactivated poliovirus type 3 that were grown from a continuous line of monkey kidney cells.

    Mixtures: Hexaxim Suspension for Injection, BOOSTRIX POLIO SUSPENSION FOR INJECTION
  9. Drug

    Promethazine

    go.drugbank.com/drugs/DB01069
    ApprovedInvestigational

    [A189901] Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.

    Categories: Antihistamines for Topical Use, Antihistamines for Systemic Use
  10. Drug

    Ensitrelvir

    go.drugbank.com/drugs/DB18834
    ApprovedInvestigational

    Ensitrelvir is under investigation in clinical trial NCT05605093 (Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)).

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use